medigraphic.com
ISSN 1561-302X (Print)

2022, Number 1

<< Back Next >>

Rev cubana med 2022; 61 (1)

Bioactive metabolites generated by intestinal dysbiosis and their pathophysiological implications in cardiovascular disease

Rodríguez PJM, Rodríguez IMM

Language: Spanish
References: 73
Page: 1-18
PDF size: 335.82 Kb.


ABSTRACT

Introduction: Dysbiosis is known as the alteration of the symbiotic relationship between the intestinal microbiota and the host is involved in the pathogenesis of atherosclerotic cardiovascular disease.
Objective: To carry out a documentary review on the pathophysiological mechanisms that relate the bioactive metabolites generated by intestinal dysbiosis with the development and progression of atherosclerotic cardiovascular disease.
Methods: The Google Scholar search engine was used and free access articles were consulted in Pubmed, SciELO, Lilacs, Cumed and Hinari databases from September 2020 to March 2021. The keywords used for this review were “microbiome”, “gut microbiota”, “dysbiosis”, “atherosclerosis”, “cardiovascular disease” and their English equivalents, according to the Health Sciences (DeCS) descriptor. Original articles, review articles, systematic reviews and meta-analyses after 2015 were considered. A total of 73 articles were reviewed.
Findings: The pathophysiological relationships between intestinal dysbiosis and cardiovascular diseases are complex, since they influence each other through their endogenous toxins (bioactive metabolites), the circulatory system, immune responses and metabolic changes. Future research should focus on elucidating the underlying molecular players and on identifying whether the pathways that interconnect gut dysbiosis with ACE are causal, correlational, or consequential.
Conclusions: The accumulated evidence supports that the dysbiosis of the intestinal microbiota is involved in the synthesis of proatherogenic metabolites which modulate the mechanisms involved in the pathophysiology of ACE.


REFERENCES

  1. Pacheco Pérez Y, Bello Fernández ZL, Góngora Parra KB. Microbioma humano, implicaciones en el proceso salud-enfermedad. Rev. Electrónica Dr. Zoilo E. Marinello Vidaurreta. 2019[acceso: 08/12/2020];44(1). Disponible en: Disponible en: http://revzoilomarinello.sld.cu/index.php/zmv/article/view/1618/pdf_545

  2. Bajinka O, Darboe A, Tan Y, Abdelhalim KA, Cham LB. Gut microbiota and the human gut physiological changes. Ann Microbiol. 2020[acceso: 14/02/2021];70(65). Disponible en: Disponible en: https://annalsmicrobiology.biomedcentral.com/articles/10.1186/s13213-020-01608-2#citeas

  3. Cucalón Arenal JM, Blay Cortés MG. Actualización en microbioma y microbiota para el médico de familia (I). Med Gen Fam. 2020[acceso: 10/02/2021];9(2). Disponible en: Disponible en: http://mgyf.org/actualizacion-en-microbioma-y-microbiota-para-el-medico-de-familia-i

  4. Illiano P, Brambilla R, Parolini C. The mutual interplay of gut microbiota, diet and human disease. The FEBS Journal. 2020[acceso: 16/02/2021];287(Issue5):833-55. Disponible en: Disponible en: https://febs.onlinelibrary.wiley.com/doi/10.1111/febs.15217

  5. Xu H, Wang X, Feng W, Liu Q, Zhou S, Liu Q, et al. The gut microbiota and its interactions with cardiovascular disease. Microbial Biotechnology. 2020[acceso: 05/04/2021];13(Issue3):637-56. Disponible en: Disponible en: https://sfamjournals.onlinelibrary.wiley.com/doi/full/10.1111/1751-7915.13524

  6. Rajendiran E, Ramadass B, Ramprasath V. Understanding connections and roles of gut microbiome in cardiovascular diseases. Canadian Journal of Microbiology. 2021[acceso: 03/04/2021];67(2). Disponible en: Disponible en: https://cdnsciencepub.com/doi/full/10.1139/cjm-2020-0043

  7. Li H, Zhang X, Pan D, Liu Y, Yan X, Tang Y, et al. Dysbiosis characteristics of gut microbiota in cerebral infarction patients. Translational Neuroscience. 2020[acceso: 07/04/2021];11(Issue1). Disponible en: Disponible en: https://www.degruyter.com/document/doi/10.1515/tnsci-2020-0117/html

  8. Pietiainen M, Liljestrand JM, Kopra E, Pussinen PJ. Mediators between oral dysbiosis and cardiovascular diseases. European Journal of Oral Sciences. 2018[acceso: 15/04/2021];126(Suppl 14):26-36. Disponible en: Disponible en: https://www.researchgate.net/publication/327421405_Mediators_between_oral_dysbiosis_and_cardiovascular_diseases#read

  9. Carrillo Salinas FJ, Anastasiou M, Ngwenyama N, Kaur K, Tai A, Smolgovsky SA, et al. Gut dysbiosis induced by cardiac pressure overload enhances adverse cardiac remodeling in a T cell-dependent manner. Gut Microbes. 2020[acceso: 08/04/2021];12(1). Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588211/citedby/

  10. Álvarez Vega M, Cortés Badilla MV, Quirós Mora LM. El impacto de la microbiota en la enfermedad cardiovascular. Revista Médica Sinergia. 2021[acceso: 12/04/2021];6(2):643. Disponible en: Disponible en: https://revistamedicasinergia.com/index.php/rms/article/view/643/1128

  11. Wilkins LJ, Monga M, Miller AW. Defining dysbiosis for a cluster of chronic diseases. Sci Rep. 2019[acceso: 05/04/2021];9. Disponible en: Disponible en: https://www.nature.com/articles/s41598-019-49452-y#citeas

  12. Moreno del Castillo MC, Valladares García J, Halabe Cherem J. Microbioma humano. Rev Fac Med (Méx.). 2018[acceso: 15/01/2021];61(6):7-19. Disponible en: Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0026-17422018000600007

  13. Gómez Eguílaz M, Ramón Trapero JL, Pérez Martínez L, Blanco JR. El eje microbiota-intestino-cerebro y sus grandes Proyecciones. Rev Neurol. 2019[acceso: 15/04/2021];68:111-17. Disponible en: Disponible en: https://www.neurologia.com/articulo/2018223

  14. Zamudio Vázquez VP, Ramírez Mayans JA, Toro Monjaraz EM, Cervantes Bustamante R, Zárate Mondragón F, Montijo Barrios E, et al. Importancia de la microbiota gastrointestinal en pediatría. Acta Pediatr Méx. 2017[acceso: 05/03/2021];38(1). Disponible en: Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0186-23912017000100049

  15. Tomoaki Ishigami LC, Kentaro Arakawa HD, Tamura K. Gut microbiota and atherosclerosis: role of B cell for atherosclerosis focusing on the gut-immune-B2 cell axis. Journal of Molecular Medicine. 2020[acceso: 05/03/2021];98:1235-44. Disponible en: Disponible en: https://link.springer.com/article/10.1007/s00109-020-01936-5

  16. Lotti Mesa RL Gutiérrez Gacel L. El eje microbiota-intestino-cerebro, futura diana terapéutica en enfermedades neurodegenerativas. Rev Neurol. 2019[acceso: 11/04/2021];69:43-44. Disponible en: Disponible en: https://www.neurologia.com/articulo/2019159

  17. Moreno Calderón X, Vialva Guerrero AA, Núñez Bello ML, Macero Esteves C, López Barrera KC, Márquez Duque AC, et al. Estudio observacional de la microbiota intestinal aeróbica. Microbiología Clínica Kasmera. 2020[acceso: 04/03/2021];48(2):e48231547. Disponible en: Disponible en: https://produccioncientificaluz.org/index.php/kasmera/article/view/31547/html

  18. Liu S, Zhao W, Liu X, Cheng L. Metagenomic analysis of the gut microbiome in atherosclerosis patients identify cross‐cohort microbial signatures and potential therapeutic target. The FASEB Journal. 2020[acceso: 05/04/2021];34(Issue11):14166-81. Disponible en: Disponible en: https://faseb.onlinelibrary.wiley.com/doi/epdf/10.1096/fj.202000622R

  19. Sebastián Domingo JJ, Sánchez Sánchez C. De la flora intestinal al microbioma. Rev Esp Enferm Dig. 2018[acceso: 03/03/2021];110(1):51-56. Disponible en: Disponible en: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082018000100009

  20. Fontané L, Benaigesa D, Godaya A, Llauradó G, Pedro Botet J. Influencia de la microbiota y de los probióticos en la obesidad. Clin Invest Arterioscl. 2018[acceso: 05/04/2021];30(6):271-76. Disponible en: Disponible en: https://www.elsevier.es/es-revista-clinica-e-investigacion-arteriosclerosis-15-articulo-influencia-microbiota-probioticos-obesidad-S0214916818300482

  21. Fan X, Jin Y, Chen G, Ma X, Zhang L. Gut microbiota dysbiosis drives the development of colorectal cancer. Digestion. 2020[acceso: 05/04/2021]:1-8. Disponible en: Disponible en: https://www.karger.com/Article/Pdf/508328

  22. Elias Oliveira J, Leite JA, Pereira ÍS, Guimarães JB, Manso GMdC, Silva JS, et alNLR and Intestinal Dysbiosis-Associated Inflammatory Illness: Drivers or Dampers? Front. Immunol. 2020[acceso: 05/04/2021];11. Disponible en: Disponible en: https://www.frontiersin.org/articles/10.3389/fimmu.2020.01810/full

  23. Peinado Martínez M, Dager Vergara I, Quintero Molano K, Mogollón Pérez M, Puello Ospina A. Síndrome Metabólico en Adultos: Revisión Narrativa de la Literatura. Archivos de Medicina. 2021[acceso: 17/04/2021];17(24):1-5. Disponible en: Disponible en: https://www.archivosdemedicina.com/medicina-de-familia/siacutendrome-metaboacutelico-en-adultos-revisioacuten-narrativa-de-la-literatura.pdf

  24. Kazemian N, Mahmoudi M, Halperin F, Wu JC, Pakpour S. Gut microbiota and cardiovascular disease: opportunities and challenges. Microbiome. 2020[acceso: 15/03/2021];8(36). Disponible en: Disponible en: https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-020-00821-0

  25. Zhigang Ren, Yajuan Fan, Ang Li, Quanquan Shen, Jian Wu, Lingyan Ren, et al. Alterations of the human gut microbiome in chronic kidney disease. Advanced Science 2020[acceso: 07/04/2021];7(Issue2). Disponible en: Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/advs.202001936

  26. Álvarez Calatayud G, Guarner F, Requena Teresa MA. Dieta y microbiota. Impacto en la salud. Nutr. Hosp. 2018[acceso: 18/03/2021];35(spe6):11-15. Disponible en: Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-16112018001200004

  27. Novakovic M, Rout A, Kingsley T, Kirchoff R, Singh A, Verma V, et al. Role of gut microbiota in cardiovascular diseases. World J Cardiol. 2020[acceso: 18/03/2021];12(4):110-22. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215967/

  28. da Luz PL, Alberton Haas E, Favarato D. Intestinal microbiota and cardiovascular diseases. Int. J Cardiovasc Sci. 2020[acceso: 05/04/2021];33(5). Disponible en: Disponible en: https://www.scielo.br/scielo.php?pid=S2359-56472020000500462&script=sci_arttext

  29. Abbasalizad Farhangi M, Vajdi M, Asghari-Jafarabadi M. Gut microbiota-associated metabolite trimethylamine N-Oxide and the risk of stroke: a systematic review and dose-response meta-analysis. Nutr J. 2020[acceso: 05/04/2021];19:76. Disponible en: Disponible en: https://nutritionj.biomedcentral.com/articles/10.1186/s12937-020-00592-2

  30. Papandreou Ch, Moré M, Bellamine A. Trimethylamine N-Oxide in relation to cardiometabolic health-cause or effect? Nutrients. 2020[acceso: 05/04/2021];12(5):1330. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284902/

  31. Liu Y, Dai M. Trimethylamine N-Oxide generated by the gut microbiota is associated with vascular inflammation: new insights into atherosclerosis. Mediators Inflamm. 2020[acceso: 25/03/2021]. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048942/

  32. Ahmad AF, Dwivedi G, O’Gara F, Caparros Martin J, Ward NC. The gut microbiome and cardiovascular disease: current knowledge and clinical potential. American Journal of Physiology-Heart and Circulatory Physiology. 2019[acceso: 09/03/2021];317(5):923-38. Disponible en: Disponible en: https://journals.physiology.org/doi/full/10.1152/ajpheart.00376.2019

  33. Sánchez Rodríguez E, Egea Zorrilla A, Plaza Díaz J, Aragón Vela J, Muñoz Quezada S, Tercedor Sánchez L, et al. The gut microbiota and its implication in the development of atherosclerosis and related cardiovascular disease. Nutrients. 2020[acceso: 02/04/2021];12(3):605. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146472/

  34. Kirichenko TV, Markina YV, Sukhorukov VN, Khotina VA, Wu W, Orekhov AN. A novel insight at atherogenesis: the role of microbiome. Front Cell Dev Biol. 2020[acceso: 12/03/2021];8. Disponible en: Disponible en: https://www.frontiersin.org/articles/10.3389/fcell.2020.586189/full

  35. Zhu Y, Shui X, Liang Z, Huang Z, Qi Y, He Y, et al. Gut microbiota metabolites as integral mediators in cardiovascular diseases (Review). International Journal of Molecular Medicine. 2020[acceso: 15/03/2021];46(Issue 3):936-48. Disponible en: Disponible en: https://www.spandidos-publications.com/10.3892/ijmm.2020.4674

  36. Landfald B, Valeur J, Berstad A, Raa J. Microbial trimethylamine-N-oxide as a disease marker: something fishy? Microb Ecol Health Dis. 2017[acceso: 04/04/2021];28(1):1327309. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444358/

  37. Jia J, Dou P, Gao M, Kong X, Li C, Liu Z, et al. Assessment of causal direction between gut microbiota-dependent metabolites and cardiometabolic health: a bidirectional Mendelian randomization analysis. Diabetes. 2019[acceso: 03/03/2021];68(9):1747-55. Disponible en: Disponible en: https://diabetes.diabetesjournals.org/content/68/9/1747.long

  38. Troseida M, Andersend GO, Broche K, Roksund Hov J. The gut microbiome in coronary artery disease and heart failure: Current knowledge and future directions. EBioMedicine. 2020[acceso: 11/04/2021];52. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016372/

  39. Eshghjoo S, Jayaraman A, Sun Y, Alaniz RC. Microbiota-mediated immune regulation in atherosclerosis. Molecules. 2021[acceso: 16/02/2021];26(179):2-11. Disponible en: Disponible en: https://www.mdpi.com/journal/molecules

  40. Li L, Zhong S, Cheng B, Qiu H, Hu Z. Cross-Talk between Gut Microbiota and the Heart: A new target for the herbal medicine treatment of heart failure? Evidence-based complementary and alternative. Medicine. 2020[acceso: 15/03/2021]:1-9. Disponible en: Disponible en: https://downloads.hindawi.com/journals/ecam/2020/9097821.pdf

  41. Kitai T, Wilson Tang WH. Impacto de la microbiota intestinal en la enfermedad cardiovascular. Rev Esp Cardiol. 2017[acceso: 07/04/2021];70(10):799-800. Disponible en: Disponible en: https://www.revespcardiol.org/es-pdf-S0300893217302737

  42. Szabo H, Hernyes A, Piroska M, Ligeti B, Fussy P, Zoldi L, et al. Association between gut microbial diversity and carotid intima-media thickness. Medicina (Kaunas). 2021[acceso: 04/04/2021];57(3):195. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996485/

  43. Zhao J, Ning X, Liu B, Dong R, Bai M, Sun S. Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review. Renal Failure. 2021[acceso: 16/03/2021];43(Issue 1). Disponible en: Disponible en: https://www.tandfonline.com/doi/full/10.1080/0886022X.2020.1864404

  44. Jazani NH, Savoj J, Lustgarten M, Ling Lau W, Vaziri ND. Impact of gut dysbiosis on neurohormonal pathways in chronic kidney disease. Diseases. 2019[acceso: 05/04/2021];7(1):21. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473882/

  45. Wu IW, Gao SS, Chou HC, Yang HY, Chang LCh, Kuo YL, et al. Integrative metagenomic and metabolomic analyses reveal severity-specific signatures of gut microbiota in chronic kidney disease. Theranostics. 2020[acceso: 13/03/2021];10(12):5398-5411. Disponible en: Disponible en: https://www.thno.org/v10p5398.htm

  46. Cigarran Guldrisa S, González Parra E, Cases Amenós A. Microbiota intestinal en la enfermedad renal crónica. Nefrología. 2017[acceso: 25/03/2021];37(1):1-114. Disponible en: Disponible en: https://www.revistanefrologia.com/es-microbiota-intestinal-enfermedad-renal-cronica-articulo-S0211699516300728

  47. Almeida C, Barata P, Fernandes R. The influence of gut microbiota in cardiovascular diseases-a brief review. Porto Biomed J. 2021[acceso: 05/04/2021];6(1):e106. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817281/

  48. Wilson Tang WH, Backhed F, Landmesser U, Hazen SL. Intestinal microbiota in cardiovascular health and disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019[acceso: 08/03/2021];73(16):2089-2105. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518422/

  49. Guasch Ferre M, Hu FB, Ruiz Canela M, Bullo M, Yu E, Zheng Y, et al. Plasma metabolites from choline pathway and risk of cardiovascular disease in the Prevention with Mediterranean Diet (PREDIMED) Study. J Am Heart Assoc. 2017[acceso: 19/03/2021];6(11):e006524. Disponible en: Disponible en: https://www.ahajournals.org/doi/10.1161/JAHA.117.006524

  50. Madan S, Mehra MR. Gut dysbiosis and heart failure: navigating the universe within. European Journal of Heart Failure. 2020[acceso: 08/03/2021];22(Issue4):629-37. Disponible en: Disponible en: https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.1792

  51. Maciezrynski LE. N-óxido de trimetilamina y su relación con la enfermedad coronaria. Revista CONAREC. 2018[acceso: 03/04/2021];34(143):28-36. Disponible en: Disponible en: http://adm.meducatium.com.ar/contenido/articulos/15500280036_1083/pdf/15500280036.pdf

  52. Dai Y, Tian Q, Si J, Sun Z, Shali S, Xu L, et al. Circulating metabolites from the choline pathway and acute coronary syndromes in a chinese case-control study. Nutr Metab (Lond). 2020[acceso: 05/03/2021];17:39. Disponible en: Disponible en: https://nutritionandmetabolism.biomedcentral.com/articles/10.1186/s12986-020-00460-0

  53. Carrero González CM, Navarro Quiroz EA, Lastre Amell G, Oróstegui Santander MA, González Gloria E, Sucerquia A, et al. Dislipemia como factor de riesgo cardiovascular: uso de probióticos en la terapéutica nutricional. AVFT Archivos Venezolanos de Farmacología y Terapéutica. 2020[acceso: 05/02/2021];39(1):126-31. Disponible en: Disponible en: https://www.revistaavft.com/images/revistas/2020/avft_1_2020/22_dislipidemia.pdf

  54. Szőke H, Kovács Z, Bókkon I, Vagedes J, Erdőfi Szabó A, Hegyi G, et al. Gut dysbiosis and serotonin: intestinal 5-HT as a ubiquitous membrane permeability regulator in host tissues, organs, and the brain. Rev Neurosci. 2020[acceso: 05/04/2021];31(4):415-25. Disponible en: Disponible en: https://www.degruyter.com/document/doi/10.1515/revneuro-2019-0095/html

  55. Yang F, Chena H, Gao Y, Anac N, Liac X, Pan X, et al. Gut microbiota-derived short-chain fatty acids and hypertension: Mechanism and treatment. Biomedicine & Pharmacotherapy. 2020[acceso: 15/03/2021];130:1-15. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S075333222030696X

  56. Sadler R, Cramer JV, Heindl S, Kostidis S, Betz D, Zuurbier KR, et al. Short-chain fatty acids improve poststroke recovery via immunological mechanisms. Journal of Neuroscience. 2020[acceso: 02/03/2021];40(5):1162-73. Disponible en: Disponible en: https://www.jneurosci.org/content/40/5/1162

  57. Calderón Pérez L, Gosalbes MJ, Yuste S, Valls RM, Pedret A, LLauradó E, et al. Gut metagenomic and short chain fatty acids signature in hypertension: a cross-sectional study. Sci Rep. 2020[acceso: 02/03/2021];10(6436). Disponible en: Disponible en: https://www.nature.com/articles/s41598-020-63475-w

  58. Vittorio Colombo A, Katie Sadler R, Llovera G, Singh V, Roth S, Heindl S, et al. Microbiota-derived short chain fatty acids modulate microglia and promote Aβ plaque deposition. eLife 2021[acceso: 13/03/2021];10:e59826. Disponible en: Disponible en: https://elifesciences.org/articles/59826

  59. de Velasco P, Ferreira A, Crovesy L, Marine T, Tavares do Carmo MD. Fatty Acids, gut microbiota, and the genesis of obesity. Biochemistry and Health Benefits of Fatty Acids. 2018[acceso: 12/04/2021]. Disponible en: Disponible en: https://www.intechopen.com/books/biochemistry-and-health-benefits-of-fatty-acids/fatty-acids-gut-microbiota-and-the-genesis-of-obesity

  60. Rüb AM, Tsakmaklis A, Gräfe SK, Simon MC, Vehreschild M, Wuethrich I. Biomarkers of human gut microbiota diversity and dysbiosis. Biomarkers in Medicine. 2021[acceso: 13/04/2021];15(2). Disponible en: Disponible en: https://www.futuremedicine.com/doi/10.2217/bmm-2020-0353

  61. Chiang JY, Ferrell JM, Wu Y, Boehme S. Bile acid and cholesterol metabolism in atherosclerotic cardiovascular disease and therapy. Cardiol Plus. 2020;5(Issue4):159-70. Disponible en: https://www.cardiologyplus.org/article.asp?issn=2470-7511;year=2020;volume=5;issue=4;spage=159;epage=170;aulast=Chiang

  62. Amabebe E, Robert FO, Agbalalah T, Orubu ESF. Microbial dysbiosis-induced obesity: role of gut microbiota in homoeostasis of energy metabolism. Br J Nutr. 2020[acceso: 08/01/2021];123(10):1127-37. Disponible en: Disponible en: https://eprints.whiterose.ac.uk/165574/

  63. González Gallegos N, González Torres YS, PadillaDurán LF. Microbiota intestinal, sobrepeso y obesidad, Revista de Salud Pública y Nutrición. 2017[acceso: 05/01/2021];16(3):23-28. Disponible en: Disponible en: https://www.medigraphic.com/pdfs/revsalpubnut/spn-2017/spn173d.pdf

  64. Kim MH, Yun KE, Kim J, Park E, Chang Y, Ryu S, et al. Gut microbiota and metabolic health among overweight and obese individuals. Sci Rep. 2020[acceso: 13/01/2021];10. Disponible en: Disponible en: https://www.nature.com/articles/s41598-020-76474-8#citeas

  65. Haleem A, Anvari S, Nazli A, Sager M, Akhtar M. An analysis of gut dysbiosis in obesity, diabetes, and chronic gut conditions. Ibnosina J Med Biomed Sci. 2020[acceso: 09/01/2021];12(Issue 4):264-71. Disponible en: Disponible en: https://www.ijmbs.org/article.asp?issn=1947-489X;year=2020;volume=12;issue=4;spage=264;epage=271;aulast=Haleem

  66. Castañeda Guillot C. Microbiota intestinal y obesidad en la infancia. Rev Cubana Pediatr. 2020[acceso: 08/03/2021];92(1):e927. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75312020000100008&lng=es&nrm=iso&tlng=es

  67. Moludi J, Maleki V, Jafari-Vayghyan H, Vaghef-Mehrabany E, Alizadeh M. Metabolic endotoxemia and cardiovascular disease: A systematic review about potential roles of prebiotics and probiotics. Clin Exp Pharmacol Physiol. 2020[acceso: 23/01/2021];47(6):927-39. Disponible en: Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1111/1440-1681.13250

  68. Sánchez Tapia M, Miller AW, Granados Portillo O, Tovar AR, Torres N. The development of metabolic endotoxemia is dependent on the type of sweetener and the presence of saturated fat in the diet. Gut Microbes. 2020[acceso: 12/02/2021];12(Issue 1). Disponible en: Disponible en: https://www.tandfonline.com/doi/full/10.1080/19490976.2020.1801301

  69. Singh R, Zogg H, Wei L, Bartlett A, Ghoshal UC, Rajender S, Ro S. Gut microbial dysbiosis in the pathogenesis of gastrointestinal dysmotility and metabolic disorders. J Neurogastroenterol Motil. 2021[acceso: 12/02/2021];27(1):19-34. Disponible en: Disponible en: http://www.jnmjournal.org/journal/view.html?doi=10.5056/jnm20149

  70. Duttaroy AK. Role of gut microbiota and their metabolites on atherosclerosis, hypertension and human blood platelet function: a review. Nutrients. 2021[acceso: 15/04/2021];13(1):144. Disponible en: Disponible en: https://www.mdpi.com/2072-6643/13/1/144

  71. Silveira Nunes G, Durso DF, Alves de Oliveira LR, Cunha EHM, Maioli TU, Vieira AT, et al. Hypertension is associated with intestinal microbiota dysbiosis and inflammation in a brazilian population. Front Pharmacol. 2020[acceso: 09/03/2021];11:258. Disponible en: Disponible en: https://www.frontiersin.org/articles/10.3389/fphar.2020.00258/full

  72. Li J, Yang X, Zhou X, Cai J. The role and mechanism of intestinal flora in blood pressure regulation and hypertension development. Antioxidants & Redox Signaling. 2021[acceso: 11/03/2021];34(10):811-30. Disponible en: Disponible en: https://www.liebertpub.com/doi/10.1089/ars.2020.8104#

  73. Katsi V, Didagelos M, Skevofilax S, Armenis I, Kartalis A, Vlachopoulos Ch, et al. GUT Microbiome-GUT Dysbiosis-Arterial Hypertension: New Horizons. Current Hypertension Reviews. 2018;14(2). Disponible en: https://www.researchgate.net/publication/325745059_Gut_Microbiome_-_Gut_Dysbiosis_-_Arterial_Hypertension_New_Horizons




2020     |     www.medigraphic.com